The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Sanofi, Eli Lilly, Gilead Sciences and Logitech International

 The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Sanofi, Eli Lilly,
                  Gilead Sciences and Logitech International

PR Newswire

CHICAGO, April 23, 2013

CHICAGO, April 23, 2013 /PRNewswire/ --Zacks.com announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Bristol-Myers Squibb Company
(NYSE:BMY), Sanofi (NYSE:SNY), Eli Lilly and Company (NYSE:LLY), Gilead
Sciences Inc. (Nasdaq:GILD) and Logitech International SA (Nasdaq:LOGI).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Get the most recent insight from Zacks Equity Research with the free Profit
from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Monday's Analyst Blog:

Bristol-Myers Likely to Report In-Line

We expect Bristol-Myers Squibb Company (NYSE:BMY) to report in line
first-quarter 2013 results before the opening bell on Apr 25.

Factors to Consider this Quarter

The genericization of Plavix (May 17, 2012) and Avapro (Mar 2012) in the US
has resulted in significant loss of revenues for Bristol-Myers. Bristol-Myers
co-developed both drugs with Sanofi (NYSE:SNY). Bristol-Myers is looking to
combat the generic threat hanging over its key drugs through partnering deals
and acquisitions and introducing new products to augment its product
portfolio. In Dec 2012, the US Food and Drug Administration cleared blood
thinner Eliquis. Successful commercialization of Eliquis should boost
Bristol-Myers' top line significantly since the drug offers great commercial
potential. Moreover, in Aug 2012, Bristol-Myers acquired Amylin
Pharmaceuticals, Inc. in a bid to diversify its business to combat the generic
threat and bolster its position in the lucrative diabetes market.

The efforts of Bristol-Myers notwithstanding, first-quarter 2013 results will
likely continue to be hurt by the genericization of Plavix and Avapro. The
company has delivered mixed results over the last four quarters, missing
estimates in two.

The Zacks Consensus Estimate for the first quarter has moved down by two cents
to 43 cents per share over the last 30 days.

Earnings Whispers?

Our proven model does not conclusively show that Bristol-Myers is likely to
beat earnings estimates this quarter. This is because a stock needs to have
both a positive earnings Expected Surprise Prediction (ESP) (Read: Zacks
Earnings ESP: A Better Method) and a Zacks Rank #1, 2 or 3 for this to happen.

Zacks ESP:The ESP, which represents the difference between the Most Accurate
estimate and the Zacks Consensus Estimate, is 0.00%. This is because both the
Most Accurate Estimate and Zacks Consensus Estimate currently stand at 41
cents.

Zacks Rank #3 (Hold): Bristol-Myers' Zacks Rank #3 lowers the predictive power
of ESP because the Zacks Rank #3 when combined with an ESP of 0.00% indicates
the possibility of in line results.

Stocks to Consider

Here are some other stocks you may want to consider as our model shows these
have the right combination of elements to post an earnings beat this season:

Eli Lilly and Company (NYSE:LLY) has an Earnings ESP of +3.85% and holds a
Zacks Rank #3 (Hold).

Gilead Sciences Inc. (Nasdaq:GILD) has an Earnings ESP of +2.08% and carries a
Zacks Rank #3.

Will Logitech Beat Earnings?

The computer and peripheral equipment company, Logitech International SA
(Nasdaq:LOGI) is set to report its fourth-quarter fiscal 2013 results on April
24. In the last reported quarter, it posted an 81.82% positive surprise. Let's
see how things are shaping up for this announcement.

Why a Likely Positive Surprise?

Our proven model shows that Logitech is likely to beat earnings because it has
the right combination of two key ingredients.

Positive Zacks ESP: Earnings Surprise Prediction or Zacks Earnings ESP, which
represents the difference between the Most Accurate Estimate and the Zacks
Consensus Estimate, is at 81.82%. This is very meaningful and a leading
indicator of a likely positive earnings surprise for shares.

Zacks #3 Rank (Neutral): Stocks with Zacks Rank #1, Zacks Rank #2 and Zacks
Rank #3 have a significantly higher chance of beating earnings. The sell rated
stocks (Zacks Rank #4 and Zacks Rank #5) should never be considered going into
an earnings announcement.

The combination of a Zacks Rank # 3 (Hold) and 81.82% ESP makes us bullish on
Logitech for the impending quarter.

What is Driving the Better than Expected Earnings?

Recently, Logitech launched a number of innovative products. The new tablet
and gaming accessories are expected to benefit the company in the long run.
Given the current trend towards smart phones and tablets, Logitech intends to
tap this high potential market through its range of accessories. In the last
reported quarter (3Q13), tablet accessories represented the best-performing
retail product category, with sales increasing a robust 119.2% year over year
to $39.4 million.

In addition, the company's cost-cutting initiatives are expected to benefit
Logitech, saving approximately $12 million to $14 million in the fourth
quarter of fiscal 2013. These savings will be primarily induced by employee
retrenchments of 140 employees, or 5% of its workforce as part of its
cost-cutting measure.

Moreover, the company is discontinuing with its non-profitable products and
businesses. The company divested its remote control and digital video security
categories with further plans to discontinue other non-profitable products,
such as speaker docks and console gaming peripherals by the end of 2013.

Want more from Zacks Equity Research? Subscribe to the free Profit from the
Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your free
subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

SOURCE Zacks Investment Research, Inc.

Website: http://www.zacks.com
 
Press spacebar to pause and continue. Press esc to stop.